If SPSP > 4, the patient with autoimmune PAP should begin treatment with WLL or inhaled GM-CSF, while the patient with secondary PAP is only treated through WLL on the basis of treating primary diseases. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.